PPCB ▲ +177.6% - Propanc Biopharma, Inc.
$PPCB Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
27-AUG-2026 08:31 AM ET
Share this post
More filings for $PPCB
PPCB ▼ -3.6% - Propanc Biopharma, Inc.Oct 26, 2026PPCB ▼ -15.6% - Propanc Biopharma, Inc.Oct 22, 2026PPCB ▼ -6.3% - Propanc Biopharma, Inc.Oct 22, 2026PPCB ▲ +5.9% - Propanc Biopharma, Inc.Oct 16, 2026PPCB ▲ +2.4% - Propanc Biopharma, Inc.Oct 14, 2026PPCB ▲ +2.0% - Propanc Biopharma, Inc.Oct 7, 2026
View full $PPCB filing history →💬 Comments
Loading comments…
Leave a comment